TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21923418

Group type: EXPERIMENTAL
Intervention: Bipolar hybrid surgery
Number of subjects: 86

Group type: COMPARATOR
Intervention: Bipolar resection of the prostate
Number of subjects: 86
Study: 19328023

Group type: EXPERIMENTAL
Intervention: 5000 IU unfractionated heparin (UFH)
Number of subjects: 183

Group type: COMPARATOR
Intervention: 2500 IU low molecular weight heparin (LMWH, dalteparin)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: UFH
Number of subjects: 183

Group type: COMPARATOR
Intervention: LMWH
Number of subjects: 183
Study: 17366247

Group type: EXPERIMENTAL
Intervention: Adherence to visits (attended >= 80% of visits)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Adherence to treatment (took >= 80% of pills)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Lost to follow-up (missed >= 3 consecutive visits)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Demographics of nonadherent women
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Demographics of women lost to follow-up
Number of subjects: 458
Study: 15111980

Group type: EXPERIMENTAL
Intervention: Extensive biopsy using intravenous conscious sedation (IVCS) (24 biopsies)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Standard biopsy using intrarectal lidocaine gel (6-12 biopsies, mean 10.1)
Number of subjects: 197
Study: 11495824

Group type: EXPERIMENTAL
Intervention: Clodronate 1,600 mg/d
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 9514482

Group type: EXPERIMENTAL
Intervention: NIDDM patients
Number of subjects: 2964
Study: 8071036

Group type: EXPERIMENTAL
Intervention: Iopromide (300 mg I/mL)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 140

Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 140
Study: 1761485

Group type: EXPERIMENTAL
Intervention: 0.5 ppm H2S
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 2.0 ppm H2S
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 5.0 ppm H2S
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (0 ppm H2S)
Number of subjects: 16
Study: 35428

Group type: EXPERIMENTAL
Intervention: Andursil
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Magnesium Trisilicate Co
Number of subjects: 1106
Study: 31494176

Group type: EXPERIMENTAL
Intervention: Constipation Assessment Scale (CAS)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Constipation treatments (1 to 2 per day)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Constipation severity evaluation over 10 weeks
Number of subjects: 175
Study: 31642581

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Multiple daily injection (MDI)
Number of subjects: 104
Study: 28039653

Group type: EXPERIMENTAL
Intervention: Phrenic nerve block (PNB) with 4 ml (30 mg) of 0.75% ropivacaine (group P, n = 28)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (group C, n = 32)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Phrenic nerve block (PNB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 60
Study: 26068548

Group type: EXPERIMENTAL
Intervention: α-keto acids (KAS) supplementation (0.2 g kg(‐1) body weight each day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 23463772

Group type: EXPERIMENTAL
Intervention: Conventional function training + additional balance exercises
Number of subjects: 113

Group type: COMPARATOR
Intervention: Conventional function training
Number of subjects: 113
Study: 21455088

Group type: EXPERIMENTAL
Intervention: Lidocaine pretreatment/saline admixture
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Saline pretreatment/lidocaine admixture
Number of subjects: 151

Group type: COMPARATOR
Intervention: Saline pretreatment/saline admixture
Number of subjects: 151
Study: 19803233

Group type: EXPERIMENTAL
Intervention: Acupoint sticking therapy at Shenque (CV 8)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Routine ward treatment of stroke (control group)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Acupoint sticking therapy
Number of subjects: 246
Study: 17155937

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg orally 1 hour before surgery (group E)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo tablet orally 1 hour before surgery (group C)
Number of subjects: 30
Study: 15103536

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural treatment programme (18 sessions)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waiting list control group (WL)
Number of subjects: 20
Study: 10872648

Group type: EXPERIMENTAL
Intervention: Teverelix 5 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Teverelix 3 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Teverelix 0.5 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Teverelix
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 9361543

Group type: EXPERIMENTAL
Intervention: General practice teaching for 5 weeks
Number of subjects: 225

Group type: COMPARATOR
Intervention: Hospital teaching for 5 weeks
Number of subjects: 225
Study: 8237139

Group type: EXPERIMENTAL
Intervention: Mianserin (20-60 mg daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (inactive)
Number of subjects: 26
Study: 3925112

Group type: EXPERIMENTAL
Intervention: Phenoxymethyl penicillin (250 mg qid) for 10 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30866666

Group type: EXPERIMENTAL
Intervention: ICD implantation
Number of subjects: 239

Group type: COMPARATOR
Intervention: RVEF
Number of subjects: 239
Study: 28521549

Group type: EXPERIMENTAL
Intervention: Topical latanoprost 0.1% lotion
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Minoxidil 5% lotion
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Betamethasone valerate 0.1% solution
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of latanoprost lotion and betamethasone valerate solution
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vehicle lotion (control group)
Number of subjects: 100
Study: 27010596

Group type: EXPERIMENTAL
Intervention: Acupuncture (weekly for 5 consecutive weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual care (physical therapy, analgesia, and/or antiinflammatory drugs)
Number of subjects: 48
Study: 24559000

Group type: EXPERIMENTAL
Intervention: Continuous enteral nutrition (ENT during 24 hours continuously)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Intermittent enteral nutrition (ENT during 18 hours with a 6‐hour nocturnal pause)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Continuous enteral nutrition
Number of subjects: 41

Group type: COMPARATOR
Intervention: Intermittent enteral nutrition
Number of subjects: 41
Study: 22118560

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (dalteparin, 5000 IU weight-adjusted dosage) with aspirin 80 mg
Number of subjects: 139

Group type: COMPARATOR
Intervention: Aspirin 80 mg alone
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin with aspirin
Number of subjects: 139
Study: 20651016

Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PV)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 202
Study: 17233681

Group type: EXPERIMENTAL
Intervention: High-intensity PRMST plus placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: High-intensity PRMST plus MA
Number of subjects: 29

Group type: COMPARATOR
Intervention: Low-resistance exercises plus placebo
Number of subjects: 29

Group type: COMPARATOR
Intervention: Low-resistance exercises plus MA
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: High-intensity PRMST
Number of subjects: 29
Study: 15836565

Group type: EXPERIMENTAL
Intervention: BoNT‐A (BOTOX)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study: 11964931

Group type: EXPERIMENTAL
Intervention: Enhanced particle filtration
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Temperature decrease
Number of subjects: 396
Study: 9788076

Group type: EXPERIMENTAL
Intervention: Multidimensional wavelet analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Established methods
Number of subjects: 0
Study: 7589040

Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2488034

Group type: EXPERIMENTAL
Intervention: Topical deoxycytidine 10(‐4) M
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 1% prednisolone phosphate
Number of subjects: 13

Group type: COMPARATOR
Intervention: Benzalkonium chloride (BAC) (0.004‐0.02%)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Thimerosal (TMS) (0.001‐0.004%)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Chlorobutanol (CHB) (0.2‐0.5%)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Trifluridine (TFT) (1.0%)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Ethyldeoxuridine (EDU) (2.0%)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Idoxuridine (IDU) (0.1%)
Number of subjects: 13

Group type: COMPARATOR
Intervention: (E)‐5(2‐bromovinyl)‐2'‐deoxyuridine (BVDU) (0.1%)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Tobramycin
Number of subjects: 13

Group type: COMPARATOR
Intervention: Amikacin
Number of subjects: 13

Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 13

Group type: COMPARATOR
Intervention: Neomycin
Number of subjects: 13
Study: 334230

Group type: EXPERIMENTAL
Intervention: Nomifensine (50-225 mg daily for 2-26 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo, imipramine, desipramine, viloxazine, nortriptyline, combination of amitriptyline and chlordiazepoxide, diazepam
Number of subjects: 0
Study: 30827001

Group type: EXPERIMENTAL
Intervention: NAC followed by gastrectomy + adjuvant chemotherapy (Arm B)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Gastrectomy + adjuvant chemotherapy with S‐1 (Arm A)
Number of subjects: 300
Study: 28294380

Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (nCPAP)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Intra-oral placebo appliance
Number of subjects: 64
Study: 26357697

Group type: EXPERIMENTAL
Intervention: Ridge Preservation (RP)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Spontaneous Healing (EXT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 22875662

Group type: EXPERIMENTAL
Intervention: Cerclage pessary
Number of subjects: 203

Group type: COMPARATOR
Intervention: Expectant management (Control)
Number of subjects: 203
Study: 21200004

Group type: EXPERIMENTAL
Intervention: GIK
Number of subjects: 217

Group type: COMPARATOR
Intervention: Control
Number of subjects: 217
Study: 19338147

Group type: EXPERIMENTAL
Intervention: Xiaoliu Baofei Pill (XBP) plus chemotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chemotherapy alone (Control)
Number of subjects: 40
Study: 17876179

Group type: EXPERIMENTAL
Intervention: EMG biofeedback-assisted relaxation (6 sessions over 4 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 24
Study: 15664791

Group type: EXPERIMENTAL
Intervention: Low-dose testosterone replacement therapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 11202817

Group type: EXPERIMENTAL
Intervention: Iontophoretically administered lidocaine (anesthetic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 0
Study: 9276197

Group type: EXPERIMENTAL
Intervention: Bromocriptine monotherapy (11 patients)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Combination therapy with bromocriptine and levodopa (35 patients)
Number of subjects: 46
Study: 8351163

Group type: EXPERIMENTAL
Intervention: Epidural morphine (0.5 mg) + Sublingual nifedipine (10 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Epidural morphine (0.5 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 3032470

Group type: EXPERIMENTAL
Intervention: CAV1 (cyclophosphamide 600 mg m‐2 i.v., adriamycin 50 mg m‐2 i.v., etoposide 500 mg m‐2 p.o. on day 3)
Number of subjects: 54

Group type: COMPARATOR
Intervention: CAV5 (cyclophosphamide and adriamycin as for CAV1, etoposide 500 mg m‐2 given in divided dose over days 3‐7)
Number of subjects: 54
Study: 29389142

Group type: EXPERIMENTAL
Intervention: Incentive condition participants received incentives for attending pre‐ and postbirth treatment contacts: $25 for each of 6 prebirth provider visits, $25-40 for each of 4 postbirth home visits, $20 for each of 5 postbirth counseling calls, and $40 for biochemically verified abstinence at Week 1 and 6-month visits.
Number of subjects: 1014

Group type: COMPARATOR
Intervention: Control condition participants received only $40 for attendance at the Week 1 and 6-month postbirth visits.
Number of subjects: 1014
Study: 28809814

Group type: EXPERIMENTAL
Intervention: Yerba Maté (YM)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 12
Study: 26576755

Group type: EXPERIMENTAL
Intervention: Face-down positioning
Number of subjects: 192

Group type: COMPARATOR
Intervention: Face-forward positioning
Number of subjects: 192
Study: 24500556

Group type: EXPERIMENTAL
Intervention: Internet blood glucose monitoring system (IBGMS)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (RT-CGM)
Number of subjects: 57

Group type: COMPARATOR
Intervention: IBGMS and RT-CGM
Number of subjects: 57
Study: 21665048

Group type: EXPERIMENTAL
Intervention: New micronized powder formulation of artemisinin (160 or 500 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Previous standard Vietnamese formulation of artemisinin
Number of subjects: 15
Study: 18280375

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gel applied during the first postoperative week
Number of subjects: 73

Group type: COMPARATOR
Intervention: 0.12% chlorhexidine rinse used during the first postoperative week
Number of subjects: 73
Study: 17065884

Group type: EXPERIMENTAL
Intervention: Protective ventilation strategy (tidal volume of 9 ml/kg during two-lung ventilation, reduced to 5 ml/kg during one-lung ventilation; positive end-expiratory pressure 5 cm H2O throughout the operative time)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Protective ventilation strategy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional ventilation strategy (tidal volume of 9 ml/kg during two-lung and one-lung ventilation; no positive end-expiratory pressure)
Number of subjects: 52
Study: 12942334

Group type: EXPERIMENTAL
Intervention: Information letter focused on workplace (n=1,468)
Number of subjects: 2164

Group type: COMPARATOR
Intervention: Information letter focused on home (n=696)
Number of subjects: 2164
Study: 10357295

Group type: EXPERIMENTAL
Intervention: Penicillin V potassium, 250 mg 3 times daily (n = 239)
Number of subjects: 478

Group type: COMPARATOR
Intervention: Penicillin V potassium, 500 mg 2 times daily (n = 239)
Number of subjects: 478
Study: 8687515

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg three times daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1920391

Group type: EXPERIMENTAL
Intervention: Slow-release carbamazepine (SR) preparation divided into two daily doses
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional carbamazepine (C) preparation divided into three daily doses
Number of subjects: 20
Study: 7038182

Group type: EXPERIMENTAL
Intervention: 10% trolamine salicylate cream
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 25
Study: 30482545

Group type: EXPERIMENTAL
Intervention: Adherence to physical activity guidelines as per REGICOR questionnaire
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Higher physical activity reported in RAPA 1 questionnaire
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Performance on chair test (> 15 vs ≤ 15 repetitions)
Number of subjects: 243
Study: 31047804

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (5·4 mg/kg or 6·4 mg/kg administered intravenously once every 3 weeks)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 44
Study: 29052025

Group type: EXPERIMENTAL
Intervention: Ultra-low-dose (ULD) technique for CTCA
Number of subjects: 82

Group type: COMPARATOR
Intervention: Routine CTCA (control group)
Number of subjects: 82
Study: 25761136

Group type: EXPERIMENTAL
Intervention: Ice condition
Number of subjects: 20

Group type: COMPARATOR
Intervention: No ice condition
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Target force at 50% of MVIC
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Target force at 20% of MVIC
Number of subjects: 20
Study: 24382118

Group type: EXPERIMENTAL
Intervention: Titanium mesh shaped on a 3D printed model of a mirrored intact orbit
Number of subjects: 57

Group type: COMPARATOR
Intervention: Ultra-high molecular weight polyethylene (UHMWPE) implant manufactured by CAM milling
Number of subjects: 57
Study: 21731015

Group type: EXPERIMENTAL
Intervention: Amphotericin B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drainage and debridement of infected necrosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fungal infection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antifungal prophylaxis
Number of subjects: 0
Study: 19832962

Group type: EXPERIMENTAL
Intervention: 405 nm wavelength
Number of subjects: 8

Group type: COMPARATOR
Intervention: 785 nm wavelength
Number of subjects: 8

Group type: COMPARATOR
Intervention: 830 nm wavelength
Number of subjects: 8
Study: 16424586

Group type: EXPERIMENTAL
Intervention: Step-and-shoot IMRT technique
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Correction method for segmental dose errors
Number of subjects: 10
Study: 14672636

Group type: EXPERIMENTAL
Intervention: Multicomponent smoking cessation intervention
Number of subjects: 561

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 561
Study: 12198327

Group type: EXPERIMENTAL
Intervention: Losartan (AIIRA)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: AIIRA with no >L-NMMA
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: >L-NMMA co-infusion
Number of subjects: 26
Study: 9790362

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (normal saline solution)
Number of subjects: 52
Study: 7487259

Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccination
Number of subjects: 237

Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 237
Study: 2270560

Group type: EXPERIMENTAL
Intervention: Single gutta-percha point with sealer (chloropercha)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Lateral condensation of gutta-percha
Number of subjects: 92
Study: 338643

Group type: EXPERIMENTAL
Intervention: 5 microgram moxestrol (R 2858)
Number of subjects: 6

Group type: COMPARATOR
Intervention: 25 microgram ethinyl estradiol
Number of subjects: 6
Study: 6623278

Group type: EXPERIMENTAL
Intervention: Whey milk product (60% liquid whey milk, 40% whole cow's milk, 0.5% skimmed milk powder)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Whole cow's milk (control)
Number of subjects: 30
Study: 30890382

Group type: EXPERIMENTAL
Intervention: 1-week 4-site ID regimen with purified Vero cell rabies vaccine (PVRV; Verorab®) without rabies immunoglobulin (RIG) (G1)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: 1-week 4-site ID regimen with PVRV and purified equine rabies immunoglobulin (pERIG) (G2)
Number of subjects: 600

Group type: COMPARATOR
Intervention: TRC 28-day 2-site ID regimen with PVRV and pERIG (G3)
Number of subjects: 600
Study: 30347561

Group type: EXPERIMENTAL
Intervention: Medication of 1 day prior to surgery (30 eyes)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Medication of 3 days prior to surgery (30 eyes)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison of dry eye classification between both groups
Number of subjects: 60
Study: 27501409

Group type: EXPERIMENTAL
Intervention: Prototype device for drug administration (scanning required before injection)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no prototype device)
Number of subjects: 10
Study: 24606876

Group type: EXPERIMENTAL
Intervention: Intervention group viewed a slideshow focused on healthy snack food affordability
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 66
Study: 22689690

Group type: EXPERIMENTAL
Intervention: pegylated IFNα2a weekly for 48 weeks
Number of subjects: 1233

Group type: EXPERIMENTAL
Intervention: albumin‐IFNα2b every 2 weeks for 48 weeks
Number of subjects: 1233
Study: 19910118

Group type: EXPERIMENTAL
Intervention: Psychological intervention (including Omnibus cognitive-behavioral therapy, relaxation therapy, and biofeedback)
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: Self-administered interventions
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: Psychological therapies
Number of subjects: 1247

Group type: COMPARATOR
Intervention: Psychological intervention
Number of subjects: 1247
Study: 18070255

Group type: EXPERIMENTAL
Intervention: Lifestyle modification programme
Number of subjects: 55

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 55
Study: 16287389

Group type: EXPERIMENTAL
Intervention: Integrative behavioral couple therapy
Number of subjects: 134

Group type: COMPARATOR
Intervention: Traditional behavioral couple therapy
Number of subjects: 134
Study: 12415022

Group type: EXPERIMENTAL
Intervention: On-call pediatrician
Number of subjects: 1182

Group type: COMPARATOR
Intervention: Nurse advice service
Number of subjects: 1182
Study: 10084000

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Guedel airway
Number of subjects: 52
Study: 8584530

Group type: EXPERIMENTAL
Intervention: salbutamol 0.2 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: fenoterol 0.2 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: salmeterol 0.05 mg
Number of subjects: 15